Hepta’s blood test identified treatment-eligible MASH patients more accurately than current non-invasive methods in a 528-patient study, according to data presented at the EASL 2026 Congress.
The new recommendations add blood-based testing and multi-target stool testing as options for average-risk adults starting at age 45.
New clinical utility data showed that offering a blood-based lung cancer test increased screening participation compared with low-dose CT screening alone.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.
Researchers have identified a blood-based biomarker panel that may identify Alzheimer’s disease patients at increased risk for brain swelling or bleeding associated with new anti-amyloid therapies.
